烟台正海生物科技股份有限公司 关联交易管理制度 烟台正海生物科技股份有限公司 第一章 总则 第一条 为充分保障中小股东的利益，确保关联交易决策的公允性，依据《中 华人民共和国公司法》、《深圳证券交易所创业板股票上市规则》（以下简称《上 市规则》）等有关法律、法规和《烟台正海生物科技股份有限公司章程》的规定， 制订本公司关联交易管理制度。 第二条 公司与关联方之间的关联交易行为除遵守有关法律、法规、规范性 文件和《公司章程》的规定外，还需遵守本制度的有关规定。 第四条 公司的关联人包括关联法人和关联自然人。 第五条 具有下列情形之一的，为公司的关联法人： （一）直接或者间接控制公司的法人或其他组织； （二）前项所述法人直接或者间接控制的除公司及其控股子公司以外的法人； （三）由第六条所列公司的关联自然人直接或者间接控制的，或者担任董事 （不含同为双方的独立董事）、高级管理人员的，除公司及其控股子公司以外的 法人或其他组织； （四）持有公司 5%以上股份的法人或者一致行动人； （五）中国证监会、证券交易所或者公司根据实质重于形式的原则认定的其 他与公司有特殊关系，可能导致公司利益对其倾斜的法人或其他组织。 第六条 ...

Group 1 - The company, Zhenghai Biological, announced the approval of several proposals during the seventh meeting of its fourth supervisory board, including the full text and summary of the 2025 semi-annual report [2]

（文章来源：证券日报） 证券日报网讯 8月4日晚间，正海生物发布公告称，公司第四届董事会第八次会议审议通过了《2025年 半年度报告全文及其摘要的议案》等多项议案。 ...

证券日报网讯8月4日晚间，正海生物（300653）发布公告称，公司将于2025年8月27日召开2025年第一 次临时股东会。本次股东会将审议《关于补选非独立董事的议案》等多项议案。 ...

正海生物2025半年报 ...

Core Insights - The company, Zhenghai Biological, reported a revenue of 188 million yuan for the first half of 2025, representing a year-on-year decline of 5.14% [1] - The net profit attributable to shareholders was 46.49 million yuan, down 45.97% compared to the previous year [1] Business Overview - The main business of the company focuses on the research, production, and sales of biological regenerative materials [1] - The company has established a comprehensive business platform that includes research and development, clinical trials, registration, production, quality assurance, and sales [1] - As of now, the company has received approval for 13 medical device products, of which 9 are classified as Class III medical devices [1] - The products are widely used in various medical fields, including oral and maxillofacial surgery, neurosurgery, orthopedics, and dermatology [1]

Core Viewpoint - Zhenghai Biological's stock closed at 23.13 yuan, with a PE ratio of 34.44, marking a new low in 84 days, and a total market capitalization of 4.163 billion yuan [1] Company Summary - Zhenghai Biological specializes in the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, skin repair membranes, surgical packing sponges, self-etching adhesives, active biological bone, dura mater patches, phosphoric acid etchants, and dental pit and fissure sealants [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023 [1] Financial Performance - For the first half of 2025, the company reported revenue of 188 million yuan, a year-on-year decrease of 5.14%, and a net profit of 46.4857 million yuan, down 45.97%, with a gross profit margin of 83.92% [1] Industry Summary - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Zhenghai Biological at 69th in the industry ranking [1] - The company's PE ratio is significantly lower than the industry average, indicating potential undervaluation [2]

Group 1 - The core viewpoint of the article is that Zhenghai Bio reported a decline in both revenue and net profit for the first half of 2025 compared to the same period in the previous year [2] - The company's operating revenue for the first half of 2025 was 188 million yuan, representing a year-on-year decrease of 5.14% [2] - The net profit attributable to the parent company was 46.49 million yuan, showing a significant year-on-year decline of 45.97% [2]

Group 1 - The company, Zhenghai Biological, announced a revenue of 188 million yuan for the first half of 2025, representing a year-on-year decrease of 5.14% [1] - The net profit attributable to shareholders of the listed company was 46 million yuan, showing a significant year-on-year decline of 45.97% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 40 million yuan, which is a year-on-year decrease of 46.77% [1]

Core Viewpoint - Zhenghai Biological reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 188 million yuan, a year-on-year decrease of 5.14% [2] - The net profit attributable to shareholders was around 46.49 million yuan, reflecting a significant year-on-year decline of 45.97% [2] - Basic earnings per share were reported at 0.26 yuan, down 45.83% compared to the previous year [2]